Search Results - "Kruegel, Brian"

Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating “clinical proof-of-concept” for AAV-neurturin (CERE-120) in Parkinson's disease by Bartus, Raymond T, Baumann, Tiffany L, Brown, Lamar, Kruegel, Brian R, Ostrove, Jeffrey M, Herzog, Christopher D

“…Abstract Neurotrophic factors have long shown promise as potential therapies for age-related neurodegenerative diseases. However, 20 years of largely…”
Get full text

Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120) by Herzog, Christopher D, Brown, Lamar, Kruegel, Brian R, Wilson, Alistair, Tansey, Malú G, Gage, Fred H, Johnson, Eugene M, Bartus, Raymond T

“…Abstract This paper reassesses the currently accepted viewpoint that targeting the terminal fields (i.e. striatum) of degenerating nigrostriatal dopamine…”
Get full text

Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: Support for nigral targeting in Parkinson's disease by Bartus, Raymond T, Brown, Lamar, Wilson, Alistair, Kruegel, Brian, Siffert, Joao, Johnson, Eugene M, Kordower, Jeffrey H, Herzog, Christopher D

“…Abstract Recent analyses of autopsied brains from subjects previously administered AAV2-neurturin (NRTN) gene transfer argues that optimizing the effects of…”
Get full text

Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease by Herzog, Christopher D, Brown, Lamar, Gammon, Dawn, Kruegel, Brian, Lin, Richard, Wilson, Alistair, Bolton, Ariadne, Printz, Marie, Gasmi, Mehdi, Bishop, Kathie M, Kordower, Jeffrey H, Bartus, Raymond T

“…Parkinson's disease is characterized by profound motor deficits that result mainly as a consequence of degeneration of midbrain dopaminergic neurons. No…”
Get full text

Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating aclinical proof-of-concepta for AAV-neurturin (CERE-120) in Parkinson's disease by Bartus, Raymond T, Baumann, Tiffany L, Brown, Lamar, Kruegel, Brian R, Ostrove, Jeffrey M, Herzog, Christopher D

“…Neurotrophic factors have long shown promise as potential therapies for age-related neurodegenerative diseases. However, 20 years of largely disappointing…”
Get full text

EXPRESSION, BIOACTIVITY, AND SAFETY 1 YEAR AFTER ADENO-ASSOCIATED VIRAL VECTOR TYPE 2-MEDIATED DELIVERY OF NEURTURIN TO THE MONKEY NIGROSTRIATAL SYSTEM SUPPORT CERE-120 FOR PARKINSON'S DISEASE. Commentaries by HERZOG, Christopher D, BROWN, Lamar, KORDOWER, Jeffrey H, BARTUS, Raymond T, FRANZ, Colin K, STARR, Philip A, GAMMON, Dawn, KRUEGEL, Brian, LIN, Richard, WILSON, Alistair, BOLTON, Ariadne, PRINTZ, Marie, GASMI, Mehdi, BISHOP, Kathie M

Get full text

513. A Simple Method To Ensure Titer Conservation of AAV2 Vector Preparations Delivered with Stainless Steel Needles by Ketchum, Elias T., Kwok, Kevin, Ramirez, Anthony, Hao, Junshan, Kruegel, Brian, Vacante, Dominick, Bartus, Raymond, Gasmi, Mehdi

“…Ceregene is developing AAV2-based gene therapy vectors encoding nerve growth factor (NGF) (CERE-110) and neurturin (NTN) (CERE-120) for the treatment of…”
Get full text

527. CERE-110, an AAV2-Based Vector To Deliver NGF, Provides Trophic Activity to Basal Forebrain Cholinergic Neurons in Rats and Cynomolgous Monkeys by Bishop, Kathie M, Hofer, Katrin, Rius, Denise, Mehta, Arpesh, Lawandry, Shokry, Brown, Lamar, Kruegel, Brian, Gasmi, Mehdi, Tuszynski, Mark, Bartus, Raymond T

“…Numerous studies indicate that providing trophic support to degenerating basal forebrain cholinergic neurons with nerve growth factor (NGF) is a logical…”
Get full text